Outpatient Behavioral Health (BH) Request – TMS Requests: Transcranial Magnetic Stimulation Precertification Information Request

#### **Applies to:**

#### **Aetna Medicare plans**

#### Innovation Health® plans

Health benefits and health insurance plans offered, underwritten and/or administered by the following:

Allina Health and Aetna Health Insurance Company (Allina Health | Aetna)

Banner Health and Aetna Health Insurance Company and/or Banner Health and

Aetna Health Plan Inc. (Banner|Aetna)

Sutter Health and Aetna Administrative Services LLC (Sutter Health | Aetna)

Texas Health + Aetna Health Plan Inc. and Texas Health + Aetna Health Insurance

Company (Texas Health Aetna)



Aetna is the brand name used for products and services provided by one or more of the Aetna group of subsidiary companies, including Aetna Life Insurance Company and its affiliates (Aetna). Aetna provides certain management services on behalf of its affiliates.

Page 1 of 6 GR-69290 (7-23)



# Outpatient Behavioral Health (BH) Request – TMS Requests: Transcranial Magnetic Stimulation Precertification Information Request

PRECERTIFICATION only. DO NOT use this form for EXTENSION requests.

#### **About this form**

Do not use in Maryland or Massachusetts for commercial plans. This form may be used for Aetna Medicare Advantage plans in these states.

You can't use this form to initiate a precertification request. To initiate a request, you have to submit your request electronically. Or you can call our Precertification Department. Failure to complete this form and submit all of the medical records we are requesting may result in the delay of review or denial of coverage.

Effective June 1, 2023, this form replaces all other Transcranial Magnetic Stimulation precertification request documents and forms. Failure to complete this form and submit all of the medical records we are requesting may result in the delay of review.

Once completed, this form contains confidential information. Only the individual or entity it's addressed to can use it. If you're not the intended recipient, or the employee or agent responsible for delivering the form to the intended recipient, you can't disseminate, distribute or copy the completed form. If you received the completed form in error, call us at 1-800-624-0756 (TTY: 711) or 1-888-632-3862 (TTY: 711).

#### How to fill out this form

As the patient's attending physician, you must complete Sections 1 through Section 6 of the form.

You can use this form with Aetna's Medicare Advantage plans. You can also use this form with health plans for which Aetna provides certain management services. This includes Innovation Health Plan, Inc. and Innovation Health Insurance Company. You can't use the form with Traditional Choice/Indemnity plans or other commercial plans. For commercial plans, call the number on the member's card to pre-certify the care.

### When you're done

Once you've filled out the form, submit it and all requested medical documentation to our Precertification Department by one of the following:

- **(Preferred)** Upload your information electronically on our secure provider website on the Provider Portal at <a href="https://www.Availity.com">www.Availity.com</a>.
- Send your information by confidential fax to:

o Aetna Leap Plans: <u>888-934-7941</u> (TTY: <u>711</u>)

o Medicare Plans: <u>959-282-8799</u> (TTY: <u>711</u>)

o Commercial Plans: 888-463-1309 (TTY: 711)

Page 2 of 6 GR-69290 (7-23)

#### What happens next?

Once we receive the requested documentation, we will perform a clinical review. Then we'll make a coverage determination and let you know our decision.

#### How we make coverage determinations

If you request precertification for a **Medicare Advantage** member, we use CMS benefit policies, including national coverage determinations (NCD) and local coverage determinations (LCD) when available, to make our coverage determinations. If there is not an available NCD or LCD to review, then the Clinical Policy Bulletin referenced below will be used as a resource in decision making.

For all other members, we encourage you to review Clinical Policy Bulletin #469: Transcranial Magnetic Stimulation and Cranial Electrical Stimulation, before you complete this form. You can find the policy by visiting the website on the back of the member's ID card.

#### **Questions?**

If you have any questions about how to fill out the form or our precertification process, call us at Aetna Leap Plans: <u>1-888-632-3862</u> (TTY: <u>711</u>) or All Other Plans: <u>1-800-424-4047</u> (TTY: <u>711</u>).

Aetna is the brand name used for products and services provided by one or more of the Aetna group of subsidiary companies, including Aetna Life Insurance Company and its affiliates (Aetna). Innovation Health is the brand name used for products and services provided by Innovation Health Insurance Company and Innovation Health Plan, Inc. Aetna and its affiliates provide certain management services for its affiliates, including Innovation Health.

Page 3 of 6 GR-69290 (7-23)



# Outpatient Behavioral Health (BH) Request -TMS Requests: Transcranial Magnetic Stimulation **Precertification Information Request**

Do not use for extension requests.

ax to		Fax number	
Behavioral Hea	alth Precert	Aetna Leap Plans: 1-888-934-7941 (TTY: 711)	
		<ul> <li>Medicare Plans: <u>1-959-282-8799</u> (TTY: <u>711</u>)</li> </ul>	
		• Commercial Plans: <u>1-888-463-1309</u> (TTY: <u>711</u> )	

Section 1	
Member name	Member telephone number
Member ID	Member date of birth / /
Facility, Physician, Provider or Vendor name	
Facility, Physician, Provider or Vendor address	
Facility, Physician, Provider or Vendor telephone number	Facility, Physician, Provider or Vendor TIN
Facility, Physician, Provider or Vendor fax number	Facility, Physician, Provider or Vendor status
1	☐ Participating ☐ Non-participating
We've received a coverage request for	
for the above member. Your reference number for an approval. Your request requires clinical review office/facility once we make a coverage determination.	·

Page 4 of 6 GR-69290 (7-23)

## **Section 2** – Provide the following general information (please write legible) Facility, Physician, Provider or Vendor name Facility, Physician, Provider or Vendor **Provider Specialty** TIN Facility, Physician, Provider or Vendor Facility, Physician, Provider or Vendor status fax number ☐ Participating Non-participating 1 -If you are a non-participating provider and this request is for Medicare: • Have you opted out of Medicare? Who referred member for TMS service (name, specialty and TIN)? Current diagnosis code(s) please include any co-occurring medical diagnosis: Was the diagnosis of Major Depression Severe confirmed by a psychiatrist? Select the CPT/HCPCS codes which best describe the service(s) you Planned start date of procedure or will provide and indicate the number of sessions requested: service ☐ 90867 \_\_\_\_\_ ☐ 90868 \_\_\_\_ ☐ 90869 \_\_\_\_\_ 1 1 Other: **Section 3** – Provide the following patient-specific information Presenting problems and symptoms: 2. Date of the most recent onset of acute symptoms: Depression rating scales that support the diagnosis of Major Depression Severe (e.g., Beck Depression Scale [BDI], Hamilton Depression Rating Scale [HDRS], Montgomery-Asberg Depression Rating Scale [MADRS], etc.)

Rating scale(s) Name, Date, and Score:

If yes MUST include note dates, number of sessions and response to treatment including rating scales

Is there a history of TMS treatment?

results and dates.

Continued

Page 5 of 6 GR-69290 (7-23)

5.	Check any	of the follo	wing that currently	exist:	
	☐ High al	cohol or ill	icit drug consumption	on   Seizure disorder/epilepsy	v − if yes, include history:
	☐ Metal ii	mplant in c	or around the head		
	Other in	mplants (e	.g. pace maker etc.	) 🔲 Other	
	☐ Neurole	ogical con	dition		
	☐ Psycho	osis			
	☐ Acute s	suicidal ris	k		
	Catato	nia			
	Life-thr	eatening in	nanition		
	☐ Cardio	vascular d	isease		
	☐ Membe	er currently	receiving ECT		
6.	If yes to ca that cleared	rdiovascular the mem	ar disease or seizur ber for TMS:	e disorder/epilepsy, provide the	name and specialty of the provider
7.	Has the Me	ember had	evidence based ps	ychotherapy known to be effective	ve for the treatment of Major
	Depression	during the	e current episode?		·
	<ul> <li>Type of</li> </ul>	therapy a	nd provider:		
	<ul> <li>Dates of</li> </ul>	of this thera	apy trial (start/finish)	):	
	<ul> <li>Freque</li> </ul>	ncy of ses	sions attended:		
		y effective		support the effectiveness, or lack	of effectiveness of therapy:
	• Railing	scales sco	ies willi dales tilat s	support the effectiveness, or faci	t of effectiveness of therapy.
8.	Please do	cument a	II psychopharmac	ologic trails (with augmentativ	e agents) during the current
8.	Please do depressiv	cument a	ll psychopharmac . Please include	ologic trails (with augmentative the dates, doses and outcome	e agents) during the current ome of each trial. Please
8.	Please do depressive describe	e episode why, incl	Il psychopharmac  Please include  Juding specific si	ologic trails (with augmentative the dates, doses and outcome de effects that led to discor	re agents) during the current ome of each trial. Please ntinuation.
8.	depressive describe For detail	e episode <b>why, inc</b> l about this	<ul> <li>Please include luding specific si s requirement see</li> </ul>	the dates, doses and outco de effects that led to discor	ome of each trial. Please ntinuation.
8.	depressive describe For detail  Comm	e episode <b>why, inc</b> l about this ercial Pla	<ul> <li>Please include luding specific si s requirement see ins: Aetna.com an</li> </ul>	ologic trails (with augmentative the dates, doses and outcome de effects that led to discortical Policy Bulletin #469 nt state available at CMS.gov	ome of each trial. Please ntinuation.
8.	depressive describe For detail  Comm	e episode <b>why, inc</b> l about this ercial Pla	<ul> <li>Please include luding specific si s requirement see ins: Aetna.com an</li> </ul>	the dates, doses and outco de effects that led to discor : d Clinical Policy Bulletin #469	ome of each trial. Please ntinuation.
8.	depressive describe For detail  Comm	e episode <b>why, inc</b> l about this ercial Pla	<ul> <li>Please include luding specific si s requirement see ins: Aetna.com an</li> </ul>	the dates, doses and outco de effects that led to discor : d Clinical Policy Bulletin #469 nt state available at CMS.gov	ome of each trial. Please ntinuation.
	depressive describe For detail  Comm	e episode <b>why, inc</b> l about this ercial Pla	e. Please include luding specific si sequirement see ins: Aetna.com an LCD for treatme	the dates, doses and outco de effects that led to discor : d Clinical Policy Bulletin #469 nt state available at CMS.gov Results of Medication	Primary or Augmenting Medication
	depressive describe For detail  Comm  Medica	e episode why, incl about this ercial Pla are Plans	e. Please include luding specific si s requirement see ins: Aetna.com an LCD for treatme	the dates, doses and outcode effects that led to discort: d Clinical Policy Bulletin #469 nt state available at CMS.gov Results of Medication Trials/Side Effects that limited	Primary or Augmenting Medication (if augmenting, indicate which
	depressive describe For detail  Comm  Medica	e episode why, incl about this ercial Pla are Plans	e. Please include luding specific si s requirement see ins: Aetna.com an LCD for treatme	the dates, doses and outcode effects that led to discort: d Clinical Policy Bulletin #469 nt state available at CMS.gov Results of Medication Trials/Side Effects that limited	Primary or Augmenting Medication (if augmenting, indicate which
	depressive describe For detail  Comm  Medica	e episode why, incl about this ercial Pla are Plans	e. Please include luding specific si s requirement see ins: Aetna.com an LCD for treatme	the dates, doses and outcode effects that led to discort: d Clinical Policy Bulletin #469 nt state available at CMS.gov Results of Medication Trials/Side Effects that limited	Primary or Augmenting Medication (if augmenting, indicate which
	depressive describe For detail  Comm  Medica	e episode why, incl about this ercial Pla are Plans	e. Please include luding specific si s requirement see ins: Aetna.com an LCD for treatme	the dates, doses and outcode effects that led to discort: d Clinical Policy Bulletin #469 nt state available at CMS.gov Results of Medication Trials/Side Effects that limited	Primary or Augmenting Medication (if augmenting, indicate which
	depressive describe For detail  Comm  Medica	e episode why, incl about this ercial Pla are Plans	e. Please include luding specific si s requirement see ins: Aetna.com an LCD for treatme	the dates, doses and outcode effects that led to discort: d Clinical Policy Bulletin #469 nt state available at CMS.gov Results of Medication Trials/Side Effects that limited	Primary or Augmenting Medication (if augmenting, indicate which
	depressive describe For detail  Comm  Medica	e episode why, incl about this ercial Pla are Plans	e. Please include luding specific si s requirement see ins: Aetna.com an LCD for treatme	the dates, doses and outcode effects that led to discort: d Clinical Policy Bulletin #469 nt state available at CMS.gov Results of Medication Trials/Side Effects that limited	Primary or Augmenting Medication (if augmenting, indicate which
Med	depressive describe For detail  Comme Medica	e episode why, incl about this ercial Pla are Plans  Dosage	e. Please include luding specific sistement see ins: Aetna.com and LCD for treatme  Dates (day/month/year)	the dates, doses and outcode effects that led to discored Clinical Policy Bulletin #469 nt state available at CMS.gov Results of Medication Trials/Side Effects that limited dosing	Primary or Augmenting Medication (if augmenting, indicate which
Med	depressive describe For detail Commet Medical ication	e episode why, incl about this ercial Pla are Plans  Dosage	p. Please include uding specific sign requirement seens: Aetna.com and LCD for treatme  Dates (day/month/year)	the dates, doses and outcode effects that led to discored to discored the control of the control	Primary or Augmenting Medication (if augmenting, indicate which antidepressant it is augmenting)
Mec Sec Any	depressive describe For detail  Comme  Medica  ication  tion 4 – I  person who	e episode why, incl about this percial Pla are Plans  Dosage  Read this knowingly	e. Please include luding specific si sequirement see ins: Aetna.com and LCD for treatme  Dates (day/month/year)  s important informy files a request for	the dates, doses and outcome de effects that led to discort described and control of the control	Primary or Augmenting Medication (if augmenting, indicate which antidepressant it is augmenting)
Med Sec Any the i	depressive describe For detail Comme Medica ication  tion 4 – I person who ntent to injure.	e episode why, incl about this ercial Pla are Plans  Dosage  Read this o knowingly ire, defraue	p. Please include luding specific sign requirement see the second and the second	the dates, doses and outcome de effects that led to discortion of coverage of a mation authorization of coverage of a mation of coverage of coverage of a mation of coverage of a mation of coverage of a mation of coverage o	Primary or Augmenting Medication (if augmenting, indicate which antidepressant it is augmenting)  edical procedure or service with atterially false information or
Sec Any the i	depressive describe For detail Comme Medica ication  tion 4 – I person who meals material	e episode why, incl about this sercial Pla are Plans  Dosage  Read this o knowingly al informa	p. Please include luding specific sign requirement see the second and the second	the dates, doses and outcode effects that led to discored to Clinical Policy Bulletin #469 nt state available at CMS.goversults of Medication Trials/Side Effects that limited dosing  mation authorization of coverage of a medical company by providing modern of misleading, commits a frauduced.	Primary or Augmenting Medication (if augmenting, indicate which antidepressant it is augmenting)
Sec Any the i	depressive describe For detail Comme Medica ication  tion 4 – I person who needs materisubjects su	e episode why, incl about this sercial Pla are Plans  Dosage  Read this o knowingly al informatich person	Dates (day/month/year)  important informent or dor deceive any instant or the purpose to criminal and civil	the dates, doses and outcode effects that led to discored to Clinical Policy Bulletin #469 nt state available at CMS.goversults of Medication Trials/Side Effects that limited dosing  mation authorization of coverage of a medical company by providing modern of misleading, commits a frauduced.	Primary or Augmenting Medication (if augmenting, indicate which antidepressant it is augmenting)  edical procedure or service with atterially false information or
Sec Any the i	depressive describe For detail  Comme Medica ication  tion 4 – I person who entent to injuste subjects su tion 5 – 9	e episode why, incl about this ercial Pla are Plans  Dosage  Read this o knowingly ire, defrauctal informatich person  Sign the	Dates (day/month/year)  important informent or dor deceive any instant or the purpose to criminal and civil	the dates, doses and outcome de effects that led to discorted and Clinical Policy Bulletin #469 nt state available at CMS.gov Results of Medication Trials/Side Effects that limited dosing  mation authorization of coverage of a medical surance company by providing modern of misleading, commits a fraudule penalties.	Primary or Augmenting Medication (if augmenting, indicate which antidepressant it is augmenting)  edical procedure or service with atterially false information or
Sec Any the i	depressive describe For detail Comme Medica ication  tion 4 – I person who needs materisubjects su	e episode why, incl about this ercial Pla are Plans  Dosage  Read this o knowingly ire, defrauctal informatich person  Sign the	Dates (day/month/year)  important informent or dor deceive any instant or the purpose to criminal and civil	the dates, doses and outcode effects that led to discored to Clinical Policy Bulletin #469 nt state available at CMS.goversults of Medication Trials/Side Effects that limited dosing  mation authorization of coverage of a medical company by providing modern of misleading, commits a frauduced.	Primary or Augmenting Medication (if augmenting, indicate which antidepressant it is augmenting)  edical procedure or service with atterially false information or

Page 6 of 6 GR-69290 (7-23)